Novartis International AG
CH-4002 Basel
Switzerland

www.novartis.com
x.com/novartisnews

PRESS RELEASE

Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS

- *Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve myelofibrosis*
- *KISQALI® six-year NATALEE analysis deepens understanding of treatment outcomes across nodal subgroups in HR+/HER2- early breast cancer*
- *SNV4818 (now RAE346) Phase I/II data mark first results since acquisition, reinforcing commitment to innovation in HR+/HER2- breast cancer through pan-mutant selective PI3Kα inhibition*
- *SCEMBLIX® longer-term ASC4START and ASC2ESCALATE data reinforce efficacy and safety profile in earlier-line CML*

Basel, November 18, 2026 – Novartis will present data from nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium (SABCS) and 68th American Society of Hematology (ASH) Annual Meeting & Exposition. Together, the data reinforce Novartis leadership in breast cancer and hematology, spanning approved medicines and a promising pipeline of next-generation therapies.

At SABCS, two late-breaking abstracts will spotlight new breast cancer data. A NATALEE nodal analysis will add to the long-term evidence for Kisqali, while SNV4818, now RAE346, will mark its first clinical data presentation following acquisition from Synnovation. At ASH, eight oral presentations will feature Novartis medicines, including 144-week Phase III MANIFEST-2 results for investigational pelabresib.

“For people living with cancer and serious blood disorders, progress means continuing to push science forward in pursuit of outcomes that meaningfully impact patients’ lives,” said Andrea Myers, Global Head, Oncology Development, Ad Interim, Novartis. “The data we’re presenting at SABCS and ASH reflect that commitment, deepening our understanding of approved and investigational medicines while advancing new approaches rooted in disease biology.”

Key SABCS data highlights include:

Abstract Title	Abstract Number / Presentation Details
Kisqali® (ribociclib)	
Six-year efficacy outcomes by nodal status from the NATALEE trial of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)	Abstract #P1-15-27 Late-breaking Poster December 9, 12:30 – 2:00 pm CT
Prognostic and predictive value of key immunohistochemistry (IHC) protein biomarker expression levels in the NATALEE trial of adjuvant ribociclib (RIB) and nonsteroidal aromatase inhibitor (NSAI) in	Abstract #RF2-2 Rapid Fire Mini Oral December 8, 5:30 – 6:30 pm CT

hormone receptor-positive/human epidermal growth factor receptor 2− early breast cancer (HR+/HER2− EBC)	
SNV4818 (now RAE346, acquired from Synnovation)	
Initial clinical results from the first-in-human phase 1/2 study of SNV4818, a highly mutant-selective PI3Ka inhibitor, in patients (pts) with PIK3CA-mutated advanced cancers, including HR+/HER2− breast cancer	Abstract #P1-4-22 Late-breaking Poster December 9, 12:30 – 2:00 pm CT

Key ASH data highlights include:

Abstract Title	**Abstract Number / Presentation Details**
Pelabresib (DAK539)	
Long-term outcomes of pelabresib (PELA) plus ruxolitinib (RUX) in Janus kinase inhibitor (JAKi)-naive myelofibrosis (MF): Week 144 results from the phase 3 MANIFEST-2 study	Abstract #525 Oral December 13, 10:00 – 10:15 am CT
Pelabresib monotherapy in high-risk essential thrombocythemia after hydroxyurea resistance or intolerance: Results from Arm 4 of the open-label, phase 2 MANIFEST study	Abstract #1038 Oral December 14, 5:45 – 7 pm CT
Scemblix® (asciminib)	
Sustained superior tolerability and patient-reported benefits with asciminib vs nilotinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the ASC4START trial	Abstract #801 Oral December 14, 11:00 – 11:15 am CT
Week 96 interim analysis (IA) of efficacy and safety in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in the first-line (1L) cohort of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)	Abstract #5507 Poster December 14, 6:00 – 8:00 pm CT
Week 96 interim analysis (IA) of efficacy and safety results in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after 1 prior tyrosine kinase inhibitor (TKI)	Abstract #1987 Poster December 12, 5:30 – 7:30 pm CT
Ianalumab (VAY736)	
Immunologic biomarker analyses of ianalumab's mechanism in primary immune thrombocytopenia from the phase 3 VAYHIT2 trial	Abstract #1251 Poster December 12, 5:45 – 7 pm CT
Rapcabtagene autoleucel (YTB323)	
Rapcabtagene autoleucel manufactured using the T-Charge™ platform preserves T cell stemness and overcomes immunosuppressive tumor microenvironments in R/R DLBCL	Abstract #436 Oral December 12, 4:45 – 5:00 pm CT
Rapcabtagene autoleucel (YTB323) phase 2 trial in patients (pts) with first-line high-risk large B-cell lymphoma (1L HR LBCL): 1 year follow-up	Abstract #1922 Poster December 12, 5:30 – 7:30 pm CT
Rapcabtagene autoleucel (YTB323) in third-line or later diffuse large B-cell lymphoma (DLBCL): Phase 2 clinical update	Abstract #3690 Poster December 13, 6:00 – 8:00 pm CT
Fabhalta® (iptacopan)	
Iptacopan demonstrates sustained hemolysis control in patients with paroxysmal nocturnal hemoglobinuria (PNH): 18-month follow-up in the APPULSE-PNH phase 3b trial	Abstract #3167 Poster December 13, 6:00 – 8:00 pm ET
Pregnancy outcomes following iptacopan exposure in patients with paroxysmal nocturnal hemoglobinuria: A descriptive analysis	Abstract #3175 Poster

NOVARTIS

December 13, 6:00 – 8:00 pm ET

Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products.

Novartis in breast cancer
For over 30 years, Novartis has been at the forefront of driving scientific advancements for individuals affected by breast cancer and enhancing clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipelines, Novartis leads the industry in discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease.

Novartis in hematology
Our legacy in hematology runs deep, shaped by over 25 years of progress, partnerships and a commitment to keep asking questions, challenging norms and striving for better answers in a uniquely complex field. In the past two decades, we have delivered more than 10 medicines across more than 15 blood cancers and serious blood disorders including leading the era of targeted therapies in cancer and bringing the first CAR-T therapy to patients.

Innovation in hematology has brought significant progress, yet patients and clinicians continue to face persistent challenges. We're forging the future of hematology, powered by our foundation in scientific discovery to deliver meaningful change for patients with unmet needs.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG's most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at **www.novartis.com** and connect with us on **LinkedIn**, **Facebook**, **X/Twitter** and **Instagram**.

Novartis Media Relations
E-mail: media.relations@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com